Meeting Videos

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment

Welcome from the IOM’s National Cancer Policy Forum (1:30 )

Welcome from the IOM’s National Cancer Policy Forum
Michael Caligiuri, The Ohio State University Comprehensive Cancer Center
Chair, National Cancer Policy Forum

Overview of the Workshop
Samir N. Khleif
Georgia Regents University Cancer Center

Samir N. Khleif, Georgia Regents University Cancer Center Planning Committee Chair

Session 1: Adoptive cell transfer
Malcolm Brenner
Baylor College of Medicine

Malcolm Brenner, Baylor College of Medicine

Session 1: Immune modulators
Naiyer Rizvi
Columbia University

Naiyer Rizvi, Columbia University

Session 1: Panel Discussion
Panelists
Institute of Medicine

Panelists field questions from the audience.

Session 1: Personalized immunotherapy
Steven Rosenberg
National Cancer Institute

Steven Rosenberg, National Cancer Institute

Session 1: Therapeutic vaccines
Jay Berzofsky
National Cancer Institute

Jay Berzofsky, National Cancer Institute

Session 2: Adoptive cell transfer
Helen Heslop
Baylor College of Medicine

Helen Heslop, Baylor College of Medicine

Session 2: Allen Wensky
Allen Wensky
FDA Center for Biologics Evaluation and Research

Allen Wensky, FDA Center for Biologics Evaluation and Research

Session 2: Discussion
Panel Discussion
Health and Medicine Division

Panelists field questions from the audience

Session 2: Immune Modulators
Alexandra Snyder Charen
Memorial Sloan Kettering Cancer Center

Alexandra Snyder Charen, Memorial Sloan Kettering Cancer Center

Session 2: Preclinical data needs to justify the launch of...
Whitney Helms
FDA Center for Drug Evaluation and Research

Whitney Helms, FDA Center for Drug Evaluation and Research

Session 2: Vaccines
Bernard Fox
Earle A. Chiles Research Institute

Bernard Fox, Earle A. Chiles Research Institute

Session 3: Biomarker integration in clinical trials for...
Lisa Butterfield
University of Pittsburgh

Lisa Butterfield, University of Pittsburgh

Session 3: Discussion
Panelists
Institute of Medicine

Panelists field questions from the audience

Session 3: FDA perspectives II
Peter Bross
FDA Center for Biologics Evaluation and Research

Peter Bross, FDA Center for Biologics Evaluation and Research

Session 3: FDA perspectives Part I
Rajeshwari Sridhara
FDA Center for Drug Evaluation and Research

Rajeshwari Sridhara, FDA Center for Drug Evaluation and Research

Session 3: Novel trial designs to assess early clinical...
Rich Simon
National Cancer Institute

Rich Simon, National Cancer Institute

Session 3: Strategies for personalized cell therapy
David Porter
University of Pennsylvania

David Porter, University of Pennsylvania

Session 3: Strategies for personalized vaccines
Harpreet Singh
Immatics Biotechnologies

Harpreet Singh, Immatics Biotechnologies

Session 4: Bio/pharma collaboration in the pre-competitive...
Steve Averbuch
Bristol Myers-Squibb

Steve Averbuch, Bristol Myers-Squibb

Session 4: Discussion
Panel
Institute of Medicine

Panelist field questions from the audience

Session 4: Infrastructure for clinical data exchange
Amy Abernethy
Flatiron Health

Amy Abernethy, Flatiron Health

Session 4: Issues in data integration and sharing for novel ...
Mary Horowitz
Medical College of Wisconsin

Mary Horowitz, Medical College of Wisconsin

Session 4: Trans-IT interoperability
Erik Perakslis
Takeda Pharmaceuticals

Erik Perakslis, Takeda Pharmaceuticals

Session 5: Addressing adverse events in immunotherapy
Ramy Ibrahim
AstraZeneca

Ramy Ibrahim, AstraZeneca

Session 5: Clinical practice and physician training needs...
Jedd Wolchok
Memorial Sloan Kettering Cancer Center

Jedd Wolchok, Memorial Sloan Kettering Cancer Center

Session 5: Discussion
Panel
Institute of Medicine

Panelists field questions from the audience

Session 5: Patient and family education
Lee Schwartzberg
Association of Community Cancer Centers

Lee Schwartzberg, Association of Community Cancer Centers

Session 5: Scaling cellular therapies for clinical use
Mark Dudley
Novartis

Mark Dudley, Novartis

Session 5: Technology assessment
Angela Thomas
UK National Health Service

Angela Thomas, UK National Health Service

Session 6: CMS perspective
James Rollins
Office of Clinical Standards and Quality

James Rollins, Office of Clinical Standards and Quality

Session 6: Discussion
Panelists
Institute of Medicine

Panelists field questions from the audience

Session 6: Health economist perspective
Scott Ramsey
Fred Hutchinson Cancer Research Center

Scott Ramsey, Fred Hutchinson Cancer Research Center

Session 6: Industry perspectives
David Kaufman
Merck

David Kaufman, Merck

Session 6: Industry perspectives
Lee Krug
Bristol Myers-Squibb

Lee Krug, Bristol Myers-Squibb

Session 6: Industry perspectives
Greg Rossi
AstraZeneca

Greg Rossi, AstraZeneca

Session 6: Patient advocacy perspective
Gwen Darien
Cancer Support Community

Gwen Darien, Cancer Support Community

Session 6: Private payer perspective
Lee Newcomer
UnitedHealthcare

Lee Newcomer, UnitedHealthcare

Welcome from the IOM’s National Cancer Policy Forum
Michael Caligiuri
National Cancer Policy Forum

Welcome from the IOM’s National Cancer Policy Forum Michael Caligiuri, The Ohio State...

Activity Staff

  • Sharyl Nass, Activity Director
  • View Full Activity Staff Roster

    • Erin Balogh

    • Cyndi Trang

    • Natalie Lubin

Activity Contact Information

For More Information Contact

Cyndi Trang
Phone:
202-334-2821
Fax:
202-334-2647
E-mail:
ctrang@nas.edu

Mailing Address


Keck Center
759A
500 Fifth St. NW
Washington, DC 20001

Video Search